Stock comparison
Nektar Therapeutics
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
NKTR
Nektar Therapeutics
Market cap
$1.33B
Sector
Healthcare
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | NKTR | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 37D | 72B | RMD |
| Benjamin Graham | 56D | 75B | RMD |
| Philip Fisher | 48D | 75B | RMD |
| Peter Lynch | 3F | 58C | RMD |
| Joel Greenblatt | 2F | 47D | RMD |
| Charlie Munger | 39D | 69B | RMD |
| Terry Smith | 43D | 73B | RMD |
Side-by-side metrics
| Metric | NKTR | RMD |
|---|---|---|
| Market cap | $1.33B | $30.31B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | - | 17.1x |
| ROIC (TTM) | -17.17% | 19.63% |
| Gross margin | 99.38% | 61.69% |
| Net margin | -2.84% | 27.44% |
| Revenue CAGR 5y | -14.2% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
NKTR leads on
- EV/EBIT-vs 17.1x+165%
- P/E (TTM)-vs 19.6x+162%
- Gross margin99.38%vs 61.69%+38%
RMD leads on
- Revenue CAGR 5y12.64%vs -14.2%+189%
- ROIC (TTM)19.63%vs -17.17%+187%
- Net margin27.44%vs -2.84%+110%
- Dividend yield1.14%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.